CJC-1295/Ipamorelin (No-DAC)

What is CJC-1295 + Ipamorelin Mix

CJC-1295 + Ipamorelin is a research blend of two peptides that act on the growth-hormone (GH) axis through different doors. Important note on naming: the CJC-1295 component supplied here is the no-DAC variant (Modified GRF 1-29) with a half-life of about thirty minutes, not the long-acting DAC-conjugated form (~6 to 8 day half-life) that some researchers expect when they say "CJC-1295". The CJC-1295 component in this blend is the no-DAC variant, also known as Mod GRF 1-29 or tetrasubstituted GRF 1-29. It is the first 29 amino acids of growth-hormone-releasing hormone (GHRH) with four substitutions that protect the molecule from rapid enzymatic breakdown. Ipamorelin is a small synthetic peptide that mimics ghrelin at the GHS-R1a receptor. Both peptides cause the pituitary to release GH, but they bind different receptors, which is why the pair is the most studied stack in published GH-secretagogue work.

We supply the two peptides as a pre-blended lyophilized (freeze-dried) powder. The CJC-1295 component is the no-DAC variant, not the long-acting albumin-binding version. The two are very different research tools and should not be confused.

How it works

The pituitary gland releases growth hormone in pulses. Two natural signals drive those pulses: GHRH from the hypothalamus, which says "make and release GH," and ghrelin from the stomach, which says "release it now." Each of the two peptides in this blend copies one of those signals.

CJC-1295 no-DAC is a stabilised GHRH 1-29 analog. Native GHRH is cleared within a few minutes by the enzyme dipeptidyl peptidase IV. The four amino-acid substitutions in this molecule slow that cleavage, extending the active window to roughly thirty minutes. That is long enough to drive a meaningful GH pulse, but short enough to leave the natural pulsatile rhythm intact. This is the key contrast with the DAC variant, which sticks to albumin for several days and produces a sustained signal of a different shape entirely.

Ipamorelin is the ghrelin-side trigger. It binds the growth-hormone-secretagogue receptor (GHS-R1a) and is the first compound in its class shown to release GH selectively, without the cortisol, prolactin, or ACTH spikes that older secretagogues produced in the same animal models. That selectivity is the reason ipamorelin is the most cited "clean" ghrelin mimetic in GH-axis research.

When the two are combined, the pituitary receives a GHRH pulse from one peptide and a ghrelin pulse from the other. The two pathways are independent and complementary. Cell-based and human research has shown that co-activation of the GHRH receptor and the GHS receptor produces a larger GH response than either signal alone, and the response stays pulsatile rather than flat.

Often studied alongside

The CJC-1295 no-DAC + Ipamorelin blend sits inside a larger family of GH-axis research peptides. Sermorelin is the unmodified GHRH 1-29 parent of the no-DAC variant, with the same receptor binding but a much shorter window before enzymatic cleavage. Tesamorelin is a different stabilised GHRH analog studied in clinical trials for visceral fat. Recombinant human growth hormone (HGH) is the downstream reference molecule that all of these secretagogues are benchmarked against.

For reconstitution, the standard solvent in published protocols is bacteriostatic or sterile water. The pre-blended powder dissolves into a clear solution.

Documentation